- Home
- AMRN vs CVRX Comparison
AMRN vs CVRX Comparison
Compare AMRN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- CVRX
- Stock Information
- Founded
- AMRN 1989
- CVRX 2000
- Country
- AMRN Ireland
- CVRX United States
- Employees
- AMRN N/A
- CVRX N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AMRN Health Care
- CVRX Health Care
- Exchange
- AMRN Nasdaq
- CVRX Nasdaq
- Market Cap
- AMRN 216.0M
- CVRX 189.0M
- IPO Year
- AMRN 1993
- CVRX 2021
- Fundamental
- Price
- AMRN $15.98
- CVRX $7.80
- Analyst Decision
- AMRN Strong Sell
- CVRX Buy
- Analyst Count
- AMRN 1
- CVRX 7
- Target Price
- AMRN $12.00
- CVRX $14.00
- AVG Volume (30 Days)
- AMRN 69.5K
- CVRX 309.8K
- Earning Date
- AMRN 07-30-2025
- CVRX 08-04-2025
- Dividend Yield
- AMRN N/A
- CVRX N/A
- EPS Growth
- AMRN N/A
- CVRX N/A
- EPS
- AMRN N/A
- CVRX N/A
- Revenue
- AMRN $219,361,000.00
- CVRX $54,652,000.00
- Revenue This Year
- AMRN N/A
- CVRX $11.32
- Revenue Next Year
- AMRN N/A
- CVRX $18.58
- P/E Ratio
- AMRN N/A
- CVRX N/A
- Revenue Growth
- AMRN N/A
- CVRX 23.11
- 52 Week Low
- AMRN $7.08
- CVRX $4.30
- 52 Week High
- AMRN $17.49
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- AMRN 59.78
- CVRX 56.11
- Support Level
- AMRN $15.54
- CVRX $7.08
- Resistance Level
- AMRN $16.50
- CVRX $7.79
- Average True Range (ATR)
- AMRN 0.48
- CVRX 0.56
- MACD
- AMRN 0.08
- CVRX -0.00
- Stochastic Oscillator
- AMRN 73.06
- CVRX 96.49
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.